{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:29:38Z","timestamp":1761611378574},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/jps.24638","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T20:48:04Z","timestamp":1442350084000},"page":"4427-4432","source":"Crossref","is-referenced-by-count":10,"title":["Preanalytical Stability of Gemcitabine and its Metabolite 2\u2032, 2\u2032-Difluoro-2\u2032-Deoxyuridine in Whole Blood\u2014Assessed by Liquid Chromatography Tandem Mass Spectrometry"],"prefix":"10.1016","volume":"104","author":[{"given":"Tormod","family":"Bj\u00e5nes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Kam\u010deva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torunn","family":"Eide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Schj\u00f8tt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asbj\u00f8rn","family":"Svardal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24638_bb0005","series-title":"Norwegian Medicines Agency. Summary of product characteristics (SPC) Gemzar","year":"2013"},{"issue":"3","key":"10.1002\/jps.24638_bb0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1002\/jps.24638_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine","volume":"41","author":"Wong","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"14","key":"10.1002\/jps.24638_bb0020","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","article-title":"Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B. 9565","volume":"18","author":"Venook","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1002\/jps.24638_bb0025","doi-asserted-by":"crossref","first-page":"072902","DOI":"10.1118\/1.4808149","article-title":"Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: A clinical case study","volume":"40","author":"Kotopoulis","year":"2013","journal-title":"Med Phys"},{"issue":"1","key":"10.1002\/jps.24638_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrel","year":"2009","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1002\/jps.24638_bb0035","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.25282","article-title":"Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer","volume":"116","author":"Tanaka","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/jps.24638_bb0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: Mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"issue":"11","key":"10.1002\/jps.24638_bb0045","first-page":"1340","article-title":"Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine","volume":"24","author":"Neff","year":"1996","journal-title":"Exp Hematol"},{"issue":"4, Suppl 11","key":"10.1002\/jps.24638_bb0050","first-page":"3","article-title":"Gemcitabine: Metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"issue":"22","key":"10.1002\/jps.24638_bb0055","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jchromb.2009.06.002","article-title":"Development of a sensitive and selective LC-MS\/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma","volume":"877","author":"Bowen","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"10.1002\/jps.24638_bb0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.cad.0000175585.24317.ca","article-title":"In vitro partition of docetaxel and gemcitabine in human volunteer blood: The influence of concentration and gender","volume":"16","author":"Dumez","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1002\/jps.24638_bb0065","series-title":"Eli Lilly Company. Highlights of prescribing information Gemzar (gemcitabine for injection)","year":"2014"},{"issue":"1\u20132","key":"10.1002\/jps.24638_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jchromb.2007.08.018","article-title":"Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma","volume":"858","author":"Khoury","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"10.1002\/jps.24638_bb0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00228-010-0799-0","article-title":"Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: Impact of the 79A>C cytidine deaminase polymorphism","volume":"66","author":"Maring","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.24638_bb0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jms.1293","article-title":"Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry","volume":"43","author":"Marangon","year":"2008","journal-title":"J Mass Spectrom"},{"key":"10.1002\/jps.24638_bb0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-9966-29-15","article-title":"Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer","volume":"29","author":"Nakata","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1002\/jps.24638_bb0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jjco\/hym171","article-title":"Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer","volume":"38","author":"Masumori","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1002\/jps.24638_bb0095","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1002\/jps.24638_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2133\/dmpk.DMPK-09-RG-099","article-title":"Human erythrocyte nucleoside transporter ENT1 functions at ice-cold temperatures","volume":"25","author":"Takano","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"14","key":"10.1002\/jps.24638_bb0105","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1016\/S0021-9258(17)47259-0","article-title":"Effect of temperature on kinetics and differential mobility of empty and loaded nucleoside transporter of human erythrocytes","volume":"259","author":"Plagemann","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.24638_bb0110","series-title":"Section H: Isotopically Modified Compounds","article-title":"Organic Chemistry Division, Commision on Nomenclature of Organic Chemistry","author":"International Union of Pure and Applied Chemistry (IUPAC)","year":"1978"},{"issue":"19","key":"10.1002\/jps.24638_bb0115","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1002\/rcm.4212","article-title":"Simultaneous quantification of 2\u2032,2\u2032-difluorodeoxycytidine and 2\u2032,2\u2032- difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry","volume":"23","author":"Jansen","year":"2009","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1002\/jps.24638_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/jps.24638_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0378-4347(94)00521-6","article-title":"Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection","volume":"665","author":"Freeman","year":"1995","journal-title":"J Chromatogr B"},{"issue":"6\u20137","key":"10.1002\/jps.24638_bb0130","first-page":"318","article-title":"Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer","volume":"28","author":"Czejka","year":"2005","journal-title":"Onkologie"},{"issue":"7","key":"10.1002\/jps.24638_bb0135","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00216-007-1267-2","article-title":"Stability of analytes in biosamples\u2014An important issue in clinical and forensic toxicology?","volume":"388","author":"Peters","year":"2008","journal-title":"Anal Bioanal Chem"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T22:02:58Z","timestamp":1653170578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0022354915000714"],"URL":"https:\/\/doi.org\/10.1002\/jps.24638","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}